Key Players
Competitive Landscape
Some supplier models competing in the familial amyloid polyneuropathy market include integrated rare-disease pharmaceutical groups, RNA-targeting biotechnology companies, gene-editing developers and oral transthyretin-stabilizer specialists.
Competition is defined by approved route coverage, treatment stage, manufacturing control, and national reimbursement access. RNA-silencing companies compete across infusion and self-administered schedules as gene-editing developers establish long-term safety for one-time treatment. Oral stabilizer suppliers depend on country-specific access decisions and specialist prescribing pathways within reimbursed healthcare systems.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Intellia Therapeutics reported advancing MAGNITUDE-2 patient screening in May 2026. | Specialist centers require evidence that one-time gene editing can replace chronic dosing without compromising long-term safety. | Gene editing remains a Phase 3 route beside recurring RNA silencers and oral stabilizers. | Trial sites can build screening and safety-monitoring experience for a potential one-time gene-editing treatment. |
| Alnylam Pharmaceuticals announced a planned USD 250 million RNA manufacturing expansion in December 2025. | Commercial RNA supply must remain dependable as treated populations and approved indications expand across regions. | The expansion adds owned enzymatic-ligation capacity for clinical and commercial siRNA supply. | Higher throughput can support future RNAi launches and reduce manufacturing constraints across the broader pipeline. |
| Purpose Pharma launched Attrogy in Germany in November 2025. | Neurologists need an authorized oral choice for adults whose disease stage and service access favor tablet treatment. | Focused rare-disease companies are commercializing established stabilization mechanisms with targeted national launches. | German access pathways can evaluate oral treatment for adults with stage 1 or stage 2 polyneuropathy. |
Ionis Pharmaceuticals, AstraZeneca, BridgeBio Pharma, Regeneron Pharmaceuticals, and Pfizer compete using approved antisense therapy, prevention research, gene-editing collaboration, and oral stabilization.
Source: Future Market Insights, Familial Amyloid Polyneuropathy Market and Transthyretin Amyloidosis Treatment Market Reports, 2026-2036.
Commercial competition spans recurring TTR suppression, oral stabilization, prevention research, and one-time gene editing across different evidence and access requirements.
Who leads the familial amyloid polyneuropathy market?
Alnylam covers intravenous and quarterly subcutaneous RNA interference routes across approved specialist polyneuropathy pathways in multiple regions. Ionis and AstraZeneca offer monthly Wainzua self-administration across specialist pathways that require national reimbursement approval. Pfizer and Purpose Pharma provide oral stabilization for defined disease stages and separate European access pathways.
Which suppliers have documented regulatory approvals?
AstraZeneca holds the European Wainzua authorization for adults with stage 1 or stage 2 polyneuropathy. Alnylam holds Onpattro and Amvuttra authorizations across specialist hereditary polyneuropathy treatment pathways in multiple regions. Pfizer and Purpose Pharma hold European approvals for oral transthyretin stabilizers used within stage-specific treatment pathways.
Which companies provide disease-modifying polyneuropathy therapies?
Alnylam provides patisiran and vutrisiran for TTR silencing using infusion and quarterly injection schedules across approved polyneuropathy pathways. Ionis and AstraZeneca provide eplontersen using monthly self-administration across approved specialist treatment pathways. Pfizer and Purpose Pharma supply oral stabilization options for defined disease stages within European reimbursement systems.
Which suppliers serve North America and Europe?
Alnylam and the Ionis-AstraZeneca alliance commercialize approved therapies across North America and Europe using established rare-disease networks. Intellia and Regeneron run a multinational gene-editing program, and BridgeBio conducts ACT-EARLY across several regions.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Alnylam Pharmaceuticals | United States and European Union | Onpattro intravenous RNAi and Amvuttra quarterly subcutaneous RNAi. A planned USD 250 million Norton manufacturing expansion was announced in December 2025. |
| Ionis Pharmaceuticals | United States and European Union with AstraZeneca | Wainua monthly antisense therapy with patient or caregiver autoinjector administration under the current United States label. |
| AstraZeneca | European Union | European marketing authorization holder for Wainzua in adults with stage 1 or stage 2 polyneuropathy. |
| Intellia Therapeutics | Multinational Phase 3 development | Nex-z one-time in vivo gene editing in the MAGNITUDE-2 Phase 3 program. |
| Regeneron Pharmaceuticals | Global collaboration with Intellia | Exact-market co-development and commercialization partner for nex-z with Intellia. |
| BridgeBio Pharma | Global Phase 3 prevention study | Acoramidis oral stabilization evaluated in ACT-EARLY for asymptomatic pathogenic TTR carriers. |
| Pfizer | European Union | Vyndaqel oral tafamidis stabilization for stage 1 polyneuropathy in authorized markets. |
| Purpose Pharma International | European Union | Attrogy oral diflunisal for stage 1 or stage 2 polyneuropathy. German availability began in November 2025. |
Competitive Landscape Research Methodology
The companies illustrate competition across approved RNA silencers, oral stabilizers, prevention studies, and gene-editing programs without implying a ranking. Current regulator records or official announcements verify each company’s exact-market therapy or program and market role. Authorizations belong to named marketing entities instead of wider corporate groups under current regulator records. The 46.0% gene silencing share is an FMI estimate for 2026 and does not allocate company shares.
